ImmunoCellular Therapeutics, Ltd., a development stage company based in Woodland Hills, California. ImmunoCellular Therapeutics focuses on developing and commercializing therapeutics to treat cancer using the immune system. Its product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens; peptide based immunotherapies targeting cancer stem cells; and monoclonal antibodies to diagnose and treat various cancers. The company is developing dendritic cell based vaccine product candidate (ICT-107) that is in Phase II clinical trial to treat glioblastoma multiforme, a type of brain tumor. It is also developing peptide based off-the-shelf vaccine, a preclinical development stage product to target multiple solid tumors; and various monoclonal antibody product candidates targeting small cell lung cancer, pancreatic cancer, multiple myeloma, and ovarian cancer.